Pharmaceutical care of rare immune-related abducens nerve adverse events induced by camrelizumab

Published on Oct. 25, 2023Total Views: 519 times Total Downloads: 272 times Download Mobile

Author: Ren-Pei LIANG ¹ Guan LIN ²  Zhang-Chao LAI ¹

Affiliation: 1. Department of Oncology, The 910th Hospital of the Chinese People’s Liberation Army Joint Logistic Support Force, Quanzhou 362000, Fujian Province, China 2. Department of Pharmacy, The 910th Hospital of the Chinese People’s Liberation Army Joint Logistic Support Force, Quanzhou 362000, Fujian Province, China

Keywords: Camrelizumab Abducens nerve palsy Adverse drug reaction Pharmaceutical care

DOI: 10.19960/j.issn.1005-0698.202311014

Reference: Ren-Pei LIANG, Guan LIN, Zhang-Chao LAI.Pharmaceutical care of rare immune-related abducens nerve adverse events induced by camrelizumab[J].Yaowu Liuxingbingxue Zazhi,2023, 32(11):1305-1310.DOI: 10.19960/j.issn.1005-0698.202311014.[Article in Chinese]  Copied

Abstract
Full-text
References

Abstract

Clinical pharmacists participated in the multiple disciplinary team treatment of 2 patients with immuno-associated abducens nerve palsy induced by camrelizumab. The clinical pharmacist identified and analyzed the causes of adverse reactions, timely suggested stopping camrelizumab and provided standardized treatment of glucocorticoid and summarized the treatment recommendations. Finally, the patients symptoms relieved significantly. Clinical pharmacists play an important role in the treatment of immuno-associated abducens nerve palsy induced by camrelizumab, suggestions on pharmaceutical care are provided for clinical drug use, to help improve the safety and efficacy of drug treatment.

Full-text

Please download the PDF version to read the full text: download

References

1.Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization[J].Cell, 2018, 175(2): 313-326. DOI: 10.1016/j.cell.2018.09.035.

2.Wang J, Su S, Li J, et al. Efficacy and safety of camrelizumab monotherapy and combination therapy for cancers: a systematic review and meta-analysis[J]. Front Oncol, 2021, 11: 695512. DOI: 10.3389/froc.2021.695512.

3.Markham A, Keam SJ. Camrelizumab: first global approval[J]. Drugs, 2019, 79(12): 1355-1361. DOI: 10.1007/s40265-019-01167-0.

4.National Cancer Institute. Common terminology criteria for adverse events(CTCAE) Version5.0[S]. 2017.

5.Zecchini JM, Kim S, Yum K, et al. Development of bell's palsy after treatment with ipilimumab and nivolumab for metastatic melanoma: a case report[J]. J Immunother, 2018, 41(1): 39-41. DOI: 10.1097/CJI.0000000000000184.

6.Altman AL, Golub JS, Pensak ML, et al. Bilateral facial palsy following ipilimumab infusion for melanoma[J].Otolaryngol Head Neck Surg, 2015, 153: 894-895. DOI: 10.1144/0194599815606701.

7.Numata S, Iwata Y, Okumura R, et al. Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: a case report[J]. J Dermatol, 2018, 45(1): 113-114. DOI: 10.1111/1346-8138.13779.

8.Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors[J]. Eur J Cancer, 2017, 82: 128-136. DOI: 10.1016/j.ejca. 2017.05.041.

9.Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies[J]. JAMA Neurol, 2017, 74: 1216-1222.DOI: 10.1001/jamaneurol.2017.1912.

10.Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders[J]. JAMA Oncol, 2016, 2: 234-240.DOI: 10.1001/ jamaneurol.2015.4368.

11.Spain L, Walls G, Julve M, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature[J]. Ann Oncol, 2017, 28(2): 377-385. DOI: 10.1093/annonc/mdw558.

12.Cappelli LC, Gutierrez AK, Bingham CO, et al. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature[J]. Arthritis Care Res (Hoboken), 2017, 69(11): 1751-1763. DOI: 10.1002/acr.23177.

13.Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer[J]. Neurology, 2018, 91(10): e985-e994. DOI: 10.1212/WNL.0000000000006124.

14.Yshii LM, Hohlfeld R, Liblau RS. Inflammatory CNS disease caused by immune check point inhibitors：shatus and perspectives[J]. Nat Rev Neurol, 2017, 13(12): 755-763. DOI: 10.1038/neneurol.2017.144.

15.Cuzzubbo S, Javeri F, Tissier M, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature[J]. Eur J Cancer, 2017, 73: 1-8. DOI: 10.1016/j.ejca.2016.12.001.

16.Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights[J]. Pituitary, 2016, 19(1): 82-92. DOI: 10.1007/s11102-015-0671-4.

17.Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy[J]. Eur J Cancer, 2016, 60: 210-225. DOI: 10.1016/j.ejca.2016.02.024.

18.史佳宇, 牛婧雯, 沈东超, 等. 免疫检查点抑制剂相关神经系统不良反应的临床诊治建议[J]. 中国肺癌杂志, 2019, 10(22): 633-638. [Shi JY, Niu JW, Shen DC, et al. Clinical diagnosis and treatment recommendations for adverse reaction in the nervous system related to immune checkpoint inhibitor[J]. Chin J Lung Cancer, 2019, 10(22): 633-638.] DOI: 10.3779/j.issn.1009-3419.2019.10.05．

19.Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update[J]. J Clin Oncol, 2021, 39: 4073-4126. DOI: 10.1200/JCO.21.01440.

20.中国临床肿瘤学会指南工作委员会, 主编. 中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南(2019版)[M]. 北京: 人民卫生出版社, 2019: 86-89.

21.中国临床肿瘤学会指南工作委员会, 主编. 中国临床肿瘤学会(CSCO)免疫检查点抑制剂相关的毒性管理指南(2021版)[M]. 北京人民卫生出版社, 2021: 130-134.